Safety of PDT-Photofrin® Prior to Lung Surgery

Inclusion Criteria: * Male or female aged 18-79 * Diagnosed with primary or metastatic tumor \< 5 cm located in peripheral lung that can be completely resectable * Candidate for surgical resection * Candidate for bronchoscopy * Tumor is accessible for unrestricted illumination of PDT * Subject is deemed likely to survive for at least 3 months * Non-menopausal/non-sterile female subject of childbearing potential has negative B-HCG (Human chorionic gonadotropin) at time of study entry * Non-menopausal/non-sterile female subject of childbearing potential uses medically acceptable form of birth control * Subject is able and willing to provide written informed consent to participate in the study, which must comply with ICH (International Council for Harmonisation) guidelines \& local requirements Exclusion Criteria: * Diagnosis of small cell lung cancer or carcinoid tumors * Primary or metastatic lung tumor located in central lung or near vertebral body * Tumor invades a major blood vessel * Presence of concurrent non-solid malignancy * Tumor previously treated with radiation therapy * Chemotherapy in the last four weeks * Tumor treated with PDT within the last 3 months * Abnormal blood results * Subject with porphyria or hypersensitivity to Photofrin * Coexisting ophthalmic disease likely to required slit-lamp exam within next 90 days * Acute or chronic medical or psychological illness as judged clinical significant to PI to preclude bronchoscopy procedures * female who is breast-feeding or intends to breast-feed during study * subject who participated in another study within last 30 days or intends to participate in another study during this study